Sense Biodetection
Sense Bio is a company focused on transforming healthcare by redefining diagnostics through the development of instrument-free, rapid molecular diagnostic technologies. Their mission is to create accessible, fast, and accurate testing solutions that can be used anywhere, enabling decentralized healthcare and improving patient outcomes. They are known for their Veros™ product platform, which offers lab-quality results in about 15 minutes without the need for complex instruments.
Industries
Nr. of Employees
medium (51-250)
Sense Biodetection
55 Chapel St. Newton, MA 02458, USA
Patents
Products
Instrument-free disposable rapid SARS-CoV-2 nucleic acid test
Single-use, self-contained nucleic acid amplification test for qualitative detection of SARS-CoV-2 RNA from nasal samples; intended for use by healthcare professionals in near-patient settings and reported to provide laboratory-quality results in approximately 15 minutes without requiring an instrument.
Instrument-free disposable rapid SARS-CoV-2 nucleic acid test
Single-use, self-contained nucleic acid amplification test for qualitative detection of SARS-CoV-2 RNA from nasal samples; intended for use by healthcare professionals in near-patient settings and reported to provide laboratory-quality results in approximately 15 minutes without requiring an instrument.
Services
Establish and operate non-exclusive distribution agreements with regional distributors to supply point-of-care molecular test kits to healthcare providers.
Design and execution of prospective multicenter clinical studies in near-patient settings to evaluate diagnostic performance and usability against laboratory qRT-PCR comparators.
Research and development of molecular amplification chemistries and integration with disposable device hardware, supported by expanded facility capacity.
Customer technical support and order handling provided via local distributors and direct support channels to assist existing and prospective customers.
Establish and operate non-exclusive distribution agreements with regional distributors to supply point-of-care molecular test kits to healthcare providers.
Design and execution of prospective multicenter clinical studies in near-patient settings to evaluate diagnostic performance and usability against laboratory qRT-PCR comparators.
Research and development of molecular amplification chemistries and integration with disposable device hardware, supported by expanded facility capacity.
Customer technical support and order handling provided via local distributors and direct support channels to assist existing and prospective customers.
Expertise Areas
- Point-of-care molecular diagnostics
- Nucleic acid amplification assay development
- Disposable diagnostic device engineering
- Multicenter clinical evaluation and diagnostic validation
Key Technologies
- Enzymatic non-thermal nucleic acid amplification
- Cartridge-based single-use diagnostic devices
- Microfluidic fluid-handling components
- Passive or simplified temperature control for assays
News & Updates
Sense announced a $50 million Series B funding round led by Koch Disruptive Technologies to support the commercialization of their Veros™ COVID-19 test and expand their product pipeline.
Timothy I. Still, an industry veteran with over 30 years of experience, was appointed as President and CEO to accelerate the company's growth and product commercialization.
Sense and Sherlock Biosciences to Collaborate on CRISPR Diagnostics
Sense will enhance its molecular diagnostics capabilities through a partnership with Sherlock Biosciences, integrating CRISPR technology for faster and more accurate tests.
Sense Expands Leadership Team for Global Launch
The company has appointed new senior executives and established a new distribution center in Boston to support the U.S. and global launch of its COVID-19 test.
CE Marking for Veros™ COVID-19 Test
The Veros™ COVID-19 test has received CE Marking, allowing it to be sold in select European countries.
Successful clinical validation of Veros™ COVID-19
The test demonstrated high accuracy and ease of use in multicenter clinical trials during the pandemic surges.
Sense announced a $50 million Series B funding round led by Koch Disruptive Technologies to support the commercialization of their Veros™ COVID-19 test and expand their product pipeline.
Timothy I. Still, an industry veteran with over 30 years of experience, was appointed as President and CEO to accelerate the company's growth and product commercialization.
Sense and Sherlock Biosciences to Collaborate on CRISPR Diagnostics
Sense will enhance its molecular diagnostics capabilities through a partnership with Sherlock Biosciences, integrating CRISPR technology for faster and more accurate tests.
Sense Expands Leadership Team for Global Launch
The company has appointed new senior executives and established a new distribution center in Boston to support the U.S. and global launch of its COVID-19 test.
CE Marking for Veros™ COVID-19 Test
The Veros™ COVID-19 test has received CE Marking, allowing it to be sold in select European countries.
Successful clinical validation of Veros™ COVID-19
The test demonstrated high accuracy and ease of use in multicenter clinical trials during the pandemic surges.